LGD-6972
CAS No. 1207989-09-0
LGD-6972( LGD6972 | RVT 1502 )
Catalog No. M10771 CAS No. 1207989-09-0
LGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 217 | Get Quote |
|
| 10MG | 321 | Get Quote |
|
| 25MG | 530 | Get Quote |
|
| 50MG | 772 | Get Quote |
|
| 100MG | 1062 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLGD-6972
-
NoteResearch use only, not for human use.
-
Brief DescriptionLGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist.
-
DescriptionLGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist; binds competitively to GCGR with high affinity and selectivity, suppressing both cAMP and glucose production in vitro; reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models in vivo.Diabetes Phase 2 Clinical.
-
In VitroIn vitro, LGD-6972 binds competitively to glucagon receptor (GCGR) with high affinity and selectivity, suppressing both cAMP and glucose production.
-
In VivoIn vivo, LGD-6972 reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models. The pharmacological activity of LGD-6972 appears to be mediated primarily by inhibiting glucagon receptor signaling.
-
SynonymsLGD6972 | RVT 1502
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number1207989-09-0
-
Formula Weight702.9008
-
Molecular FormulaC43H46N2O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 31 mg/mL
-
SMILESCC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)C(CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C
-
Chemical NameEthanesulfonic acid, 2-[[4-[(2R)-2-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-3-oxo-3-[(2',4',6'-trimethyl[1,1'-biphenyl]-4-yl)amino]propyl]benzoyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
des-His1-[Glu9]-Gluc...
Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats.
-
GLP-1R Antagonist 1
GLP-1R Antagonist 1 is an orally active, CNS penetrant and non-competitive glucagon-like peptide 1 receptor (GLP-1R) antagonist (IC50: 650 nM).
-
GLP-1R agonist 3
GLP-1R agonist 3 is a potent imidazole derivative and GLP-1R agonist with demonstrated research potential in diabetes. [Thickened]
Cart
sales@molnova.com